MedTrace Logo

Cardiac Resynchronization Therapy, Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure (CHF)

NCT00700700 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2011-07-06

No results posted yet for this study

Summary

A new therapy for patients with advanced heart failure (HF) involves the implantation of a specialized pacemaker device (Cardiac Resynchronization Therapy, CRT) that attempts to restore the synchronized contraction of the ventricular chambers of the heart. In some people, CRT improves exertional breathlessness and allows them to exercise for longer periods. However, to date, the mechanisms by which CRT improves symptoms and exercise tolerance is unknown. This study will use in-depth cardiopulmonary exercise testing and pulmonary function testing to explore these mechanisms in greater detail.

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

Active Cardiac Resynchronization Therapy (CRT)

Initiation of active biventricular pacing/cardiac resynchronization therapy Devices by Medtronic: 1. Insync Sentry 7298 \& 7299 2. Concerto C174 ASK (Most frequently implanted) 3. Insync III 8042 (PM) Devices by Guidant/Boston Scientific: 1. Contak Renewal 4 H190 \& H199 2. Contak Renewal 3 H127 Devices by ELA/Sorin: 1\. Ovatio CRT 6750

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Chris M. Parker, MD, MSc · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700700 on ClinicalTrials.gov